
Pfizer Ends Development of Its Obesity Pill
Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday that it would stop studying danuglipron after a participant in …